This company listing is no longer active
BCEL Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Atreca, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.09 |
| 52 Week High | US$1.18 |
| 52 Week Low | US$0.052 |
| Beta | 1.03 |
| 11 Month Change | -2.17% |
| 3 Month Change | -40.00% |
| 1 Year Change | -92.17% |
| 33 Year Change | -98.85% |
| 5 Year Change | -99.47% |
| Change since IPO | -99.50% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation
Jul 23
Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?
Dec 08Atreca GAAP EPS of -$0.72 misses by $0.02
Aug 08Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation
Jun 18Atreca: Biotech With Promise Based On First Candidate ATRC-101
Apr 22Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?
Mar 05Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case
Jan 25Atreca: Safety Data Brought Down Stock
Sep 10Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?
Sep 02We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth
May 14Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares
Jan 29We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth
Dec 07
Atreca EPS misses by $0.06
Nov 12Shareholder Returns
| BCEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 2.2% |
| 1Y | -92.2% | 18.3% | 32.6% |
Return vs Industry: BCEL underperformed the US Biotechs industry which returned 5.5% over the past year.
Return vs Market: BCEL underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| BCEL volatility | |
|---|---|
| BCEL Average Weekly Movement | 21.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BCEL's share price has been volatile over the past 3 months.
Volatility Over Time: BCEL's weekly volatility has decreased from 29% to 21% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 90 | John Orwin | www.atreca.com |
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria.
Atreca, Inc. Fundamentals Summary
| BCEL fundamental statistics | |
|---|---|
| Market cap | US$3.57m |
| Earnings (TTM) | -US$97.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs BCEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCEL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$97.76m |
| Earnings | -US$97.76m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCEL perform over the long term?
See historical performance and comparison